تقرير
GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
العنوان: | GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease. |
---|---|
المؤلفون: | Sun R; Sickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA., Srivastava A; Division of Nephrology, University of Illinois Chicago, Chicago, Illinois, USA., Derebail VK; UNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Han J; Sickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.; Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA., Molokie RE; Sickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.; Department of Medicine, Jesse Brown VA Medical Center, Chicago, Illinois, USA., Gordeuk V; Sickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA., Saraf SL; Sickle Cell Center, Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA. |
المصدر: | American journal of hematology [Am J Hematol] 2024 Aug; Vol. 99 (8), pp. 1610-1612. Date of Electronic Publication: 2024 Apr 24. |
نوع المنشور: | Letter; Research Support, N.I.H., Extramural |
اللغة: | English |
بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: New York Ny : Wiley-Blackwell Original Publication: New York, Liss. |
مواضيع طبية MeSH: | Anemia, Sickle Cell*/drug therapy , Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use, Humans ; Adult ; Male ; Female ; Middle Aged ; Glucagon-Like Peptide 1/agonists ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Sodium-Glucose Transporter 2 |
References: | Ataga KI, Saraf SL, Derebail VK. The nephropathy of sickle cell trait and sickle cell disease. Nat Rev Nephrol. 2022;18:361‐377. Rangaswami J, Bhalla V, de Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific Statement from the American Heart Association. Circulation. 2020;142:e265‐e286. Inker LA, Eneanya ND, Coresh J, et al. New creatinine‐ and cystatin C‐based equations to estimate GFR without race. N Engl J Med. 2021;385:1737‐1749. Inker LA, Collier W, Greene T, et al. A meta‐analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29:1867‐1876. Zhou J, Han J, Nutescu EA, et al. Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six‐year population‐based cohort analysis. Br J Haematol. 2019;185:116‐127. The E‐KCG, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117‐127. |
معلومات مُعتمدة: | HL153161 United States HL NHLBI NIH HHS; HL153161 United States HL NHLBI NIH HHS |
المشرفين على المادة: | 0 (Sodium-Glucose Transporter 2 Inhibitors) 89750-14-1 (Glucagon-Like Peptide 1) 0 (Hypoglycemic Agents) 0 (Sodium-Glucose Transporter 2) |
تواريخ الأحداث: | Date Created: 20240424 Date Completed: 20240709 Latest Revision: 20240802 |
رمز التحديث: | 20240802 |
DOI: | 10.1002/ajh.27348 |
PMID: | 38655752 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1096-8652 |
---|---|
DOI: | 10.1002/ajh.27348 |